Genetic Analysis launches consumer microbiome testing platform through Prokarimi, powered by GA-map® technology

OSLO, NORWAY – August 8, 2024: Microbiome DX company Genetic Analysis AS ("GA") announces the completion and launch of a consumer microbiome testing platform in partnership with Prokarimi AS ("Prokarimi"). This strategic initiative marks GA’s presence in the Nordic consumer market via its partner, offering an accessible and user-friendly microbiome gut health testing service.

As communicated in December 2023, GA and Comono AS established a Joint Venture—Prokarimi—to develop a digital gut health testing platform targeting the consumer market, with an initial launch planned for Q2 2024. Today, we are pleased to announce Prokarimi´s successful platform launch in Norway, with plans to enroll in the rest of the Nordic consumer market.

The consumer platform leverages GA’s validated microbiome testing technology, extensive bacteria database, and its partner’s expertise in building advanced software solutions. Initially targeting the Nordic market through online channels and select specialist retail stores, the service is designed for scalability, with plans for future expansion into Europe, the US, and Asia. The launch aligns with GA’s strategic focus on supplying the growing demand for high-quality, standardized microbiome tests.  The service will deliver precise, actionable insights into gut health, addressing a significant unmet need among consumers.

GA’s CEO, Ronny Hermansen comments:

"We’re thrilled that our partner has successfully completed the development and launch of the GA-map® based consumer microbiome testing platform. The consumer health market needs reliable, user-friendly microbiome tests offering actionable insights into gut health. The collaboration between GA and Comono allows Prokarimi to bring a high-quality digital solution to Nordic consumers, with the potential for seamless international expansion. GA’s standardized gut testing platform, combined with Prokarimi’s digital platform, positions us to set a new standard in consumer microbiome testing”, says Ronny Hermansen, CEO of Genetic Analysis.

To review Prokarimi's offering, visit the website: www.prokarimi.no

Link to the previous press release, published in December 2023: https://www.genetic-analysis.com/genetic-analysis-partners-up-to-enter-the-consumer-market-with-ga-map/

For more information about GA, please contact:

Ronny Hermansen, CEO

E-mail: rh@genetic-analysis.com

About the Microbiome consumer testing market

More than 20% of the Western population is suffering from gut-related problems such as Irritable Bowel Syndrome (IBS), and this prevalence is increasing. Post the COVID-19 pandemic, there is a growing trend within wellness, healthy lifestyle, and self-testing, and the microbiome testing market is expected to increase significantly in the coming years. Reliable market size statistics for consumer gut microbiome testing in Europe is lacking. However, a good indication of the importance and potential growth of the market is illustrated by looking at the European probiotics market, which is expected to reach USD 18.76 billion by 2028, growing at a CAGR of 7%. The size of the probiotics market illustrates a willingness among consumers to spend money related to gut health, highlighting the interest and need for microbiome testing. (https://www.arizton.com/market-reports/europe-probiotics-market)

For further information, please contact:
Ronny Hermansen, Chief Executive Officer
E-mail: rh@genetic-analysis.com

About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering.

For more general information: www.genetic-analysis.com

Stay updated on GA and sign up for more investor-related information: https://www.genetic-analysis.com/subscriptions/

Interested in reading more about GA's products? Please visit ga-map.com